Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WS016 dry suspension for hyperkalemia
CTR20232290Phase 2Completed
- Sponsor
- Waterstone Pharmaceuticals
- Start
- Jul 2023
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of WS016 in hyperkalemia, sponsored by Waterstone Pharmaceuticals. Started Jul 2023; status: completed.
02
Drugs
WS016
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on CTR20232290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232290.